HCA Healthcare (NYSE:HCA) Earns “Buy” Rating from Truist Financial

Posted by George Bondi on Nov 3rd, 2026

HCA Healthcare (NYSE:HCA – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Truist Financial in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $510.00 target price on the stock, up from their previous target price of $495.00. Truist Financial‘s target price would indicate a potential upside of 9.04% from the stock’s current price.

Several other research analysts also recently weighed in on HCA. Wall Street Zen upgraded shares of HCA Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday. Royal Bank Of Canada upped their price objective on HCA Healthcare from $496.00 to $521.00 and gave the stock an “outperform” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft set a $476.00 target price on HCA Healthcare in a report on Monday, July 27th. Barclays boosted their price target on HCA Healthcare from $387.00 to $401.00 and gave the company an “equal weight” rating in a report on Thursday, October 29th. Finally, Wells Fargo & Company upped their price target on HCA Healthcare from $381.00 to $468.00 and gave the stock an “equal weight” rating in a research report on Monday. Sixteen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $480.13.

Read Our Latest Research Report on HCA

HCA Healthcare Stock Down 0.0%

NYSE:HCA traded down $0.02 on Tuesday, hitting $467.71. The stock had a trading volume of 258,649 shares, compared to its average volume of 1,340,521. The business’s 50-day simple moving average is $438.21 and its two-hundred day simple moving average is $444.84. The stock has a market cap of $101.26 billion, a price-to-earnings ratio of 15.51, a price-to-earnings-growth ratio of 1.53 and a beta of 1.10. HCA Healthcare has a 52-week low of $353.99 and a 52-week high of $556.52.

HCA Healthcare (NYSE:HCA – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The company reported $7.22 EPS for the quarter, beating the consensus estimate of $6.65 by $0.57. The firm had revenue of $19.85 billion during the quarter, compared to analyst estimates of $19.33 billion. HCA Healthcare had a net margin of 8.61% and a negative return on equity of 198.52%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.96 EPS. As a group, equities research analysts anticipate that HCA Healthcare will post 30.15 EPS for the current year.

Institutional Investors Weigh In On HCA Healthcare

Institutional investors have recently bought and sold shares of the business. MidFirst Bank bought a new position in shares of HCA Healthcare in the second quarter worth about $28,000. Clearstead Trust LLC purchased a new position in HCA Healthcare in the 2nd quarter worth approximately $29,000. Latitude Advisors LLC bought a new position in HCA Healthcare in the 3rd quarter worth approximately $32,000. Cedar Mountain Advisors LLC purchased a new stake in HCA Healthcare during the 1st quarter valued at approximately $33,000. Finally, Delos Wealth Advisors LLC purchased a new stake in HCA Healthcare during the 2nd quarter valued at approximately $35,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

More HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

Positive Sentiment: Growth investment in Cape Coral: HCA plans to build a roughly $300 million hospital in Cape Coral, Florida, with the city providing approximately $31 million in incentives. The facility could expand HCA’s capacity and support future revenue growth, although construction and ramp-up costs will precede the benefits. Cape Coral Lands $300M HCA Hospital, City Backs It With $31M in Incentives
Positive Sentiment: Improved analyst expectations: KeyCorp issued a stronger EPS estimate for HCA, suggesting analysts see continued earnings momentum following the company’s recent quarterly earnings beat. HCA Healthcare Stock Gets Stronger EPS Estimate from KeyCorp
Positive Sentiment: Higher price target: One analyst raised HCA’s price target to $521, implying meaningful upside relative to the reference price and providing support for the stock’s valuation. HCA Healthcare Price Target Raised to $521
Neutral Sentiment: Wells Fargo remains cautious: Wells Fargo raised its target to $468 but maintained an “equal weight” rating, indicating the firm sees limited near-term upside at current levels. Wells Fargo HCA Healthcare rating
Neutral Sentiment: New senior notes offering: An HCA subsidiary plans to issue senior notes. The financing may provide capital for operations, refinancing or expansion, but it also increases debt obligations and interest costs. HCA Healthcare launches fresh senior notes offering
Negative Sentiment: Data breach disclosure: A cybersecurity incident reportedly affected about 55,000 people, creating potential costs, regulatory exposure and reputational risk. HCA data breach hits 55,000 people
Negative Sentiment: Payer pressure: Reports warn that reimbursement and insurance-payer challenges could weigh on HCA’s 2027 outlook, potentially limiting margins and earnings growth. HCA Healthcare stock faces payer pressure ahead of 2027 outlook

About HCA Healthcare

(Get Free Report)

HCA Healthcare, Inc is a healthcare services company that operates hospitals, ambulatory surgery centers, emergency care facilities, physician practices and other healthcare sites. Its facilities provide a broad range of services, including acute and emergency care, surgery, cardiology, oncology, women’s and children’s services, behavioral health and outpatient care.

The company serves patients primarily across the United States through a network of healthcare facilities in numerous states.